Summary: We are evaluating the effects of a novel tumor growth inhibitor (specific small molecule inhibitor of beta catenin) in dogs with either primary appendicular osteosarcoma or pulmonary lesions consistent with metastasis of appendicular osteosarcoma (post amputation).
Study Procedures: Dogs will be administered an intravenous infusion of investigational product up to twice per week for the initial 4 weeks, then weekly thereafter. Primary or pulmonary metastatic lesions will be radiographically assessed at baseline and after weeks 2, 4, and 6 weeks of treatment. CT scans may be assessed at baseline and after 6 weeks of treatment. Continuing study treatment is available for dogs completing the 6-week initial study.
To qualify for participation, your dog must:
- Be ≥9 months of age, neutered or intact, and ≥2.5 kg (5.5 lbs)
- Have biopsy confirmed diagnosis of appendicular osteosarcoma
Dogs will not be eligible for participation if:
- Not likely to complete the 6-week study, in poor health or are not eating.
- Have palpable, enlarged regional lymph nodes likely associated with osteosarcoma metastasis (due to poorer prognosis).
- On current treatment with any chemotherapeutic agent at time of enrollment.
- Received chemotherapy within a week prior to enrollment.
- Have radiographic evidence of congestive heart failure or cardiomyopathy.
Additional inclusion and exclusion criteria may be required to qualify for study participation
The study procedures are at no cost to dog owners. Dog owners will be reimbursed for time and effort.